Invitae - Invitae Launches Full Access to its Liquid-Based …
https://ir.invitae.com/news-and-events/press-releases/press-release-details/2022/Invitae-Launches-Full-Access-to-its-Liquid-Based-Personalized-Cancer-Monitoring-Platform-to-Help-Detect-Disease-Earlier/default.aspx
WEBSAN FRANCISCO, March 17, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced full access to its Personalized Cancer Monitoring (PCM TM) platform to help detect minimal or molecular residual disease (MRD) in patients with solid tumors.
DA: 88 PA: 84 MOZ Rank: 44